Why the study?
Updated 2019 ESC/EAS recommendations formulated new approaches to cardiovascular risk assessment and correction of dyslipidemia, warranting discussion of their clinical application.
The updated 2019 ESC/EAS guidelines recommend more aggressive LDL-C lowering and introduce new targets for various cardiovascular risk categories to reduce cardiovascular events.
The high incidence of cardiovascular disease leads to a routine individual assessment of the patient's cardiovascular risk, and to the correction of the therapy. In 2019, at the European Congress of Cardiology, updated recommendations of the ESC/EAS (European Society of Cardiology / European Atherosclerosis Society) on the diagnosis and treatment of dyslipidemia were presented, new approaches to cardiovascular risk assessing and correction of dyslipidemia were formulated. The article discusses the main aspects of clinical application of the new recommendations for the treatment of this pathology.
No takes yet. Share an insight, caveat, or question.
Пырочкин et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: